JP2006518737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518737A5 JP2006518737A5 JP2006503216A JP2006503216A JP2006518737A5 JP 2006518737 A5 JP2006518737 A5 JP 2006518737A5 JP 2006503216 A JP2006503216 A JP 2006503216A JP 2006503216 A JP2006503216 A JP 2006503216A JP 2006518737 A5 JP2006518737 A5 JP 2006518737A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- agent
- binding
- construct
- targetable construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 47
- 230000008685 targeting Effects 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 108090000790 Enzymes Proteins 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000003053 toxin Substances 0.000 claims 8
- 231100000765 toxin Toxicity 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000005556 hormone Substances 0.000 claims 5
- 229940088597 hormone Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- -1 CD66a-d Proteins 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 150000001639 boron compounds Chemical class 0.000 claims 4
- 239000002532 enzyme inhibitor Substances 0.000 claims 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims 4
- 239000003667 hormone antagonist Substances 0.000 claims 4
- 239000002955 immunomodulating agent Substances 0.000 claims 4
- 229940121354 immunomodulator Drugs 0.000 claims 4
- 230000002584 immunomodulator Effects 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 239000000049 pigment Substances 0.000 claims 3
- 239000007790 solid phase Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 claims 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 102100031196 Choriogonadotropin subunit beta 3 Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 1
- 101000776619 Homo sapiens Choriogonadotropin subunit beta 3 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001038874 Homo sapiens Glycoprotein hormones alpha chain Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 1
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108010010590 Human beta Subunit Chorionic Gonadotropin Proteins 0.000 claims 1
- 102000015872 Human beta Subunit Chorionic Gonadotropin Human genes 0.000 claims 1
- 101710123134 Ice-binding protein Proteins 0.000 claims 1
- 101710082837 Ice-structuring protein Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 102100022497 Mucin-3A Human genes 0.000 claims 1
- 102100022693 Mucin-4 Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 102000043276 Oncogene Human genes 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 1
- 102100035194 Placenta growth factor Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100038126 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000003134 recirculating effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44435703P | 2003-01-31 | 2003-01-31 | |
| US60/444,357 | 2003-01-31 | ||
| PCT/US2004/002768 WO2004074434A2 (en) | 2003-01-31 | 2004-02-02 | Methods and compositions for administering therapeutic and diagnostic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006518737A JP2006518737A (ja) | 2006-08-17 |
| JP2006518737A5 true JP2006518737A5 (enExample) | 2007-03-08 |
| JP4874090B2 JP4874090B2 (ja) | 2012-02-08 |
Family
ID=32908405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503216A Expired - Fee Related JP4874090B2 (ja) | 2003-01-31 | 2004-02-02 | 治療薬および診断薬を投与するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7534431B2 (enExample) |
| EP (1) | EP1587550B1 (enExample) |
| JP (1) | JP4874090B2 (enExample) |
| CN (1) | CN1767860A (enExample) |
| AT (1) | ATE517638T1 (enExample) |
| AU (1) | AU2004213752B2 (enExample) |
| CA (1) | CA2514277C (enExample) |
| IL (1) | IL169896A (enExample) |
| MX (1) | MXPA05008222A (enExample) |
| WO (1) | WO2004074434A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| WO2003074567A2 (en) * | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| EP1587550B1 (en) * | 2003-01-31 | 2011-07-27 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| JP2007524412A (ja) * | 2004-01-22 | 2007-08-30 | イムノメディクス， インコーポレイテッド | 葉酸コンジュゲートおよびコンプレックス |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| US20070128116A1 (en) * | 2005-07-27 | 2007-06-07 | Wang Zheng J | Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs |
| US20100015044A1 (en) * | 2005-08-03 | 2010-01-21 | Robert Qiu | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| US8080534B2 (en) * | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| MX2008009970A (es) * | 2006-02-01 | 2008-11-19 | Univ Johns Hopkins | Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos. |
| AU2007249488B2 (en) * | 2006-05-15 | 2011-11-10 | Immunonomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| EP2076257A4 (en) * | 2006-09-15 | 2014-04-16 | Belrose Pharma Inc | POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS |
| CA2686933A1 (en) * | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| MX2010001194A (es) * | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| JP5468015B2 (ja) | 2008-01-08 | 2014-04-09 | アクセリア ファーマシューティカルズ | 抗菌ペプチド系に対する作動薬 |
| US8475763B2 (en) * | 2008-10-09 | 2013-07-02 | Actis, Ltd. | Method of determining the course of treatment for a patient having adenocarcinoma |
| US8512728B2 (en) * | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| JP5789821B2 (ja) * | 2009-12-04 | 2015-10-07 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | タンパク質、ペプチドおよび他の分子の改善されたｆ−１８標識化のための方法および組成物 |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| US10167319B2 (en) * | 2010-05-29 | 2019-01-01 | Ben-Gurion University Of Negev Research & Development Authority | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications |
| CN103476429B (zh) | 2010-09-03 | 2016-08-24 | 施特姆森特克斯股份有限公司 | 新型调节剂及使用方法 |
| US10702614B2 (en) | 2011-02-15 | 2020-07-07 | Albert Einstein College Of Medicine | Radiobacteria for therapy of cancer |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| US20130231583A1 (en) * | 2012-03-02 | 2013-09-05 | Donna Rekkerth | Methods and Compositions for Injection Delivery |
| KR102133611B1 (ko) | 2012-06-14 | 2020-07-13 | 마이크로벤션, 인코포레이티드 | 중합체 치료 조성물 |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| WO2014062696A1 (en) | 2012-10-15 | 2014-04-24 | Microvention, Inc. | Polymeric treatment compositions |
| JP6064601B2 (ja) | 2013-01-09 | 2017-01-25 | オムロンヘルスケア株式会社 | 超音波式吸入器用の薬液槽および薬液パック |
| CA2898363A1 (en) * | 2013-01-17 | 2014-07-24 | Sit Soft Intelligent Therapeutics Gmbh & Co Kg | Selective cell death-inducing binary enzyme system |
| AU2014214843A1 (en) * | 2013-02-07 | 2015-05-21 | Immunomedics, Inc. | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| CN113045660B (zh) | 2013-03-13 | 2023-09-01 | 伊麦吉纳博公司 | 与cd8的抗原结合构建体 |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| US9388243B2 (en) * | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| JP6270264B2 (ja) * | 2014-02-04 | 2018-01-31 | 株式会社ミツトヨ | 情報処理装置、情報処理方法、プログラム、測定装置、及び測定方法 |
| US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| AU2015328370B2 (en) | 2014-10-07 | 2021-08-05 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| US10126298B2 (en) | 2015-05-04 | 2018-11-13 | Arman Nabatian | Hydrogels containing embedded substrates for targeted binding of molecules |
| EP3303370A4 (en) | 2015-05-28 | 2019-03-13 | Immunomedics, Inc. | T20-CONSTRUCTS FOR THERAPY AND / OR VACCINES AGAINST HIV (HUMAN IMMUNODEFICIENCY VIRUS) |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| US11007272B1 (en) | 2016-10-07 | 2021-05-18 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| WO2018085050A1 (en) * | 2016-11-03 | 2018-05-11 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for imaging tissues and tumors |
| EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| WO2019074965A1 (en) * | 2017-10-09 | 2019-04-18 | Microvention, Inc. | EMBOLIC RADIOACTIVE LIQUID |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| EP3801217A4 (en) | 2018-05-30 | 2022-07-20 | Zap Surgical Systems, Inc. | RADIOSURGICAL NEUROMODLATION CLOSE TO CRITICAL STRUCTURES |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CA3236930A1 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US4150149A (en) | 1976-11-29 | 1979-04-17 | Professional Staff Association Of The Los Angeles County Harbor General Hospital | Method and means for the early detection and diagnosis of certain types of cancers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US4460459A (en) | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| EP0643583B1 (en) | 1992-05-06 | 2000-07-26 | Immunomedics, Inc. | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| US5914312A (en) * | 1992-06-09 | 1999-06-22 | Neorx Corporation | Pretargeting methods and compounds |
| DE69331319T2 (de) * | 1992-06-09 | 2002-08-08 | Neorx Corp., Seattle | Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren |
| US5846741A (en) | 1992-08-21 | 1998-12-08 | Immunomedics, Inc. | Boron neutron capture therapy using pre-targeting methods |
| US6120768A (en) | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
| WO1995015978A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| ATE306930T1 (de) * | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US5965115A (en) | 1997-11-05 | 1999-10-12 | The Procter & Gamble Company | Personal care compositions |
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| JP4113670B2 (ja) * | 1998-06-22 | 2008-07-09 | イムノメディクス， インコーポレイテッド | プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用 |
| ATE499115T1 (de) * | 1998-09-18 | 2011-03-15 | Immunomedics Inc | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US20030162709A1 (en) * | 2001-12-26 | 2003-08-28 | Edmund Rossi | Methods of generating multispecific, multivalent agents from VH and VL domains |
| CN100522999C (zh) * | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| US20040018557A1 (en) * | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| ES2871905T3 (es) * | 2002-03-01 | 2021-11-02 | Immunomedics Inc | Inmunoconjugado que comprende anticuerpos de RS7 humanizados |
| WO2003074567A2 (en) * | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| JP4083507B2 (ja) * | 2002-08-28 | 2008-04-30 | セイコーインスツル株式会社 | 半導体装置の製造方法 |
| EP1587550B1 (en) * | 2003-01-31 | 2011-07-27 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| US7172751B2 (en) * | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
| CN101484182B (zh) * | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
-
2004
- 2004-02-02 EP EP04737253A patent/EP1587550B1/en not_active Expired - Lifetime
- 2004-02-02 US US10/768,707 patent/US7534431B2/en not_active Expired - Fee Related
- 2004-02-02 JP JP2006503216A patent/JP4874090B2/ja not_active Expired - Fee Related
- 2004-02-02 AT AT04737253T patent/ATE517638T1/de not_active IP Right Cessation
- 2004-02-02 WO PCT/US2004/002768 patent/WO2004074434A2/en not_active Ceased
- 2004-02-02 CN CNA2004800090642A patent/CN1767860A/zh active Pending
- 2004-02-02 AU AU2004213752A patent/AU2004213752B2/en not_active Ceased
- 2004-02-02 MX MXPA05008222A patent/MXPA05008222A/es active IP Right Grant
- 2004-02-02 CA CA2514277A patent/CA2514277C/en not_active Expired - Fee Related
-
2005
- 2005-07-26 IL IL169896A patent/IL169896A/en active IP Right Grant
-
2009
- 2009-04-09 US US12/420,864 patent/US7892547B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 US US12/985,775 patent/US8097252B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006518737A5 (enExample) | ||
| EP1720575B1 (en) | Therapeutic and diagnostic conjugates for use with multispecific antibodies | |
| CA2916671C (en) | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | |
| US8038983B2 (en) | Fluorinated carbohydrate conjugates | |
| AU2003209446B2 (en) | Bispecific antibody point mutations for enhancing rate of clearance | |
| US7560110B2 (en) | Production and use of novel peptide-based agents with bispecific antibodies | |
| AU2003283599C1 (en) | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics | |
| JP2006514627A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JPH02504630A (ja) | ２成分系医薬 | |
| JP7364584B2 (ja) | 抗体薬物複合体の製造方法 | |
| TW200530187A (en) | 3-cyano-quinoline derivatives with antiproliferative activity | |
| US20070048227A1 (en) | Multispecific noncovalent complexes for delivery of therapeutics | |
| CN118401258A (zh) | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 | |
| HK40005822A (en) | Antibody-sn-38 immunoconjugates with a cl2a linker |